NAXUS® is an arabinoxylan extract from wheat that has been shown to slow down glucose absorption in several clinical studies, thus avoiding excessive glucose peaks, and thereby lowering the insulin response. EFSA has approved a health claim for blood glucose control. NAXUS is further a potent prebiotic.
BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition and healthcare industry. BioActor’s Medical Affairs Manager, Bouke Salden, will present promising results from a recently completed clinical study on the effects of NAXUS® on gut barrier function at the Digestive Disease Week 2015 in Washington. It is considered the largest and most prestigious meeting in the world for the GI professional, that attracts more than 14,000 physicians, researchers and academics from around the world who aim to stay up-to-date in the field.
The meeting is the year’s best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery, prevention, diagnosis and treatment of digestive disorders, and cutting-edge technological advances.